Loading organizations...
Antios Therapeutics was an Atlanta, Georgia-based clinical-stage biopharmaceutical company focused on developing innovative targeted therapies to treat and potentially cure viral diseases, primarily chronic hepatitis B virus infections. The organization centered its core research and development efforts on its lead drug candidate, ATI-2173, which successfully reached Phase 2 clinical trials before facing a strict FDA clinical hold in May 2022 due to safety reports. Prior to officially filing for Chapter 11 bankruptcy protection in March 2023, the enterprise operated with a small team of under 50 employees and raised over $190 million in total venture funding. This capital included a $75 million Series C financing round backed by prominent lead investors such as Lumira Ventures, Forbion, and Abingworth. Antios Therapeutics was founded in 2018 by Abel De La Rosa, Richard Colonno, and Karl Hostetler.
Antios Therapeutics has raised $196.0M across 3 funding rounds.
Antios Therapeutics has raised $196.0M in total across 3 funding rounds.
Antios Therapeutics has raised $196.0M in total across 3 funding rounds.
Antios Therapeutics's investors include EPIQ Capital Group, Craig Gordon, Domain Associates, Pontifax Venture Capital, Adage Capital Management, Aisling Capital, Altium Capital, Amzak Health, Avego Bioscience Capital, CAM Capital, Delos Capital, Granite Point Capital.
Antios Therapeutics has raised $196.0M across 3 funding rounds. Most recently, it raised $75.0M Series B in November 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2021 | $75M Series B | Epiq Capital Group, Craig Gordon | Domain Associates, Pontifax Venture Capital, Adage Capital Management, Aisling Capital, Altium Capital, Amzak Health, Avego Bioscience Capital, CAM Capital, Delos Capital, Granite Point Capital, GRA Venture Fund, Heartland Healthcare Capital, Lifesci Venture Partners, Lumira Ventures, RA Capital Management, Sixty Degree Capital, Soleus Capital | Announced |
| Apr 1, 2021 | $96M Series B | GUY Levy | Domain Associates, Michele Park, Pontifax Venture Capital, Sanofi Ventures, Adage Capital Management, Aisling Capital, Amzak Health, CAM Capital, Delos Capital, Granite Point Capital, Lifesci Venture Partners, Lumira Ventures, RA Capital Management, Sixty Degree Capital | Announced |
| Nov 1, 2018 | $25M Series A | Domain Associates, Benjamin Rovinski, Ph.d. | Pontifax Venture Capital | Announced |
Antios Therapeutics is a clinical-stage biopharmaceutical company developing innovative antiviral therapies, primarily targeting chronic Hepatitis B (HBV), a disease affecting 250 million people worldwide and a leading cause of liver cirrhosis and liver cancer.[2][3][4] Its lead candidate, ATI-2173, is a novel antiviral that directly targets the liver to prevent HBV DNA replication, aiming for a lasting functional cure, while the company has pursued other HBV-focused assets like capsid and polymerase inhibitors.[2][5] Antios serves patients with viral diseases, addressing unmet needs in HBV treatment through a team experienced in antiviral drug development and commercialization.[2][4]
The company operates in the biopharma sector with a focus on pressing public health challenges, backed by venture capital financing and a pipeline that includes discontinued programs like ATI-2173, ATI-1645, and ATI-1428, indicating prior clinical advancement up to at least Phase 2 trials starting in 2021-2022.[5] Growth momentum appears tempered by pipeline discontinuations, but its leadership positions it to potentially revive or pivot efforts in antivirals.[2][4][5]
Antios Therapeutics emerged as a biopharma venture focused on viral diseases, with no specific founding year detailed in available records, but its pipeline shows clinical trials initiating as early as 2021 (e.g., ATI-1428 on October 28, 2021).[5] The company is led by a skilled team with proven experience in developing and commercializing successful antiviral drugs, humanizing its mission through expertise in tackling HBV—a global epidemic.[2][4] Key early traction came from advancing multiple HBV candidates: ATI-2173 targeting HBV polymerase, ATI-1645 and ATI-1428 as capsid inhibitors, with trials starting in 2022 (e.g., March 29 and April 11).[5] The idea stemmed from identifying HBV's replication mechanisms as a high-unmet-need target, positioning Antios to deliver functional cures where current therapies fall short.[2]
Antios rides the wave of advancing antiviral innovation, particularly for HBV where no cure exists despite 250 million chronic cases driving liver disease burdens.[2] Timing aligns with rising demand for functional cures amid stalled big pharma efforts and post-pandemic focus on resilient antiviral platforms. Market forces like venture funding for biopharma (evidenced by Antios's backers) and HBV's public health priority favor it, especially with FDA incentives for orphan-like viral indications.[4][5] Antios influences the ecosystem by validating novel mechanisms like liver-targeted inhibitors, potentially inspiring competitors and accelerating HBV pipeline development despite its own setbacks.[2][5]
Antios's path forward likely involves pipeline revival or new HBV assets, leveraging its antiviral expertise amid growing investor interest in curative therapies. Trends like AI-driven drug design and combination regimens for HBV will shape its journey, with potential for partnerships if it reignites clinical momentum. Its influence could evolve from niche innovator to key player if it overcomes discontinuations, ultimately redefining viral disease treatment like its tech-inspired precision promises—blossoming from early promise into broader impact.
